A phase I study of toripalimab, an anti-PD-1 antibody, in patients with refractory malignant solid tumors.
Wei XL, Ren C, Wang FH, Zhang Y, Zhao HY, Zou BY, Wang ZQ, Qiu MZ, Zhang DS, Luo HY, Wang F, Yao S, Xu RH.
Wei XL, et al. Among authors: zhang ds, zhang y.
Cancer Commun (Lond). 2020 Aug;40(8):345-354. doi: 10.1002/cac2.12068. Epub 2020 Jun 26.
Cancer Commun (Lond). 2020.
PMID: 32589350
Free PMC article.
Clinical Trial.